PR 002
Alternative Names: PR-002Latest Information Update: 22 Dec 2023
At a glance
- Originator Paragon Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 22 Dec 2023 Preclinical trials in Unspecified in USA (Parenteral) before December 2023 (Paragon Therapeutics pipeline, December 2023)
- 28 Dec 2022 Early research in Unspecified in USA (Parenteral) (Paragon Therapeutics pipeline, December 2022)